BDTX
NASDAQBlack Diamond Therapeutics Inc.
Price$2.09-0.02 (-0.95%)
01:30 PM07:45 PM
News · 26 weeks25-33%
2025-12-072026-05-31
Mix1690d
- SEC Filings8(50%)
- Other6(38%)
- Insider2(13%)
Latest news
25 items- PRBlack Diamond Therapeutics to Participate in Jefferies Global Healthcare ConferenceCAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Velleca, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026, in New York, NY. In addition, the company will host one-on-one meetings with investors on the same day. Presentation details are as follows: 4:55-5:25pm ET on Wednesday, June 3 The Webcast will be available at the start of the presentation under "Events and Presentations" on the Invest
- SECBlack Diamond Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Black Diamond Therapeutics, Inc. (0001701541) (Filer)
- PRBlack Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical MutationsPreliminary mPFS of 15.2 months; mDOR not reachedRobust CNS activity, with 86% CNS ORR; no patients developed de novo brain metastasesORR 60% in patients with a broad spectrum of EGFR-NCMs, including PACCDose dependent and manageable AE profile, no new safety signals observedWebcast on Thursday, May 21, 2026 at 5:30 pm EDT CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced positive results from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer (NSCLC) patients with
- PRBlack Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLCWebcast will be held Thursday, May 21, 2026, at 5:30 p.m. ET CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast for investors to present updated results from its ongoing Phase 2 trial of silevertinib in frontline patients with EGFR mutated non-small cell lung cancer on Thursday, May 21, 2026, at 5:30 p.m. ET. Webcast information The webcast can be accessed under "Events and Presentations" on the Investors section of the Black Diamond website at www.blackdiamondtherapeutics.com. A replay o
- PRBlack Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateOral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC patients, including preliminary DOR and PFS data, to take place at the 2026 ASCO Annual MeetingFirst patient dosed in the Phase 2 trial of silevertinib in patients with newly diagnosed EGFRvIII+ GBMCash, cash equivalents, and investments of $118.3 million as of March 31, 2026, expected to be sufficient to fund operations into 2H of 2028 CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the first quarte
- SECSEC Form 10-Q filed by Black Diamond Therapeutics Inc.10-Q - Black Diamond Therapeutics, Inc. (0001701541) (Filer)
- SECBlack Diamond Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Black Diamond Therapeutics, Inc. (0001701541) (Filer)
- SECSEC Form DEFA14A filed by Black Diamond Therapeutics Inc.DEFA14A - Black Diamond Therapeutics, Inc. (0001701541) (Filer)
- SECSEC Form DEF 14A filed by Black Diamond Therapeutics Inc.DEF 14A - Black Diamond Therapeutics, Inc. (0001701541) (Filer)
- PRBlack Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual MeetingPoster also to be presented on the Phase 2 data of silevertinib in recurrent EGFRm NSCLC patients Trial-in-progress poster to be presented on the randomized Phase 2 trial of silevertinib in patients with newly diagnosed EGFRvIII-positive GBM CAMBRIDGE, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced multiple presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 – June 2, 2026, in Chicago. Details for the Oral Presentation: Session Type/Title: Rapid Oral
- INSIDERSEC Form 4 filed by Behbahani Ali4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
- INSIDERSEC Form 4 filed by Raman Prakash4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
- SECSEC Form S-8 filed by Black Diamond Therapeutics Inc.S-8 - Black Diamond Therapeutics, Inc. (0001701541) (Filer)
- SECSEC Form 10-K filed by Black Diamond Therapeutics Inc.10-K - Black Diamond Therapeutics, Inc. (0001701541) (Filer)
- SECBlack Diamond Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Black Diamond Therapeutics, Inc. (0001701541) (Filer)
- PRBlack Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateClinical update on track for Q2 2026 for Phase 2 trial of silevertinib in patients with non-classical EGFRm NSCLC, including preliminary DOR and PFS data in frontline settingCompany is preparing to initiate a randomized Phase 2 trial of silevertinib in patients with newly diagnosed EGFR altered GBM in Q2 2026 Cash, cash equivalents, and investments of $128.7 million as of December 31, 2025, expected to be sufficient to fund operations into 2H of 2028 CAMBRIDGE, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today r
- PRBlack Diamond Therapeutics to Participate in Upcoming Investor ConferencesCAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D. and Chief Scientific Officer Elizabeth Buck, Ph.D., are as follows: 46th Annual TD Cowen Healthcare Conference presentation at 1:10pm ET on Wednesday, March 4, 202625th Annual Needham Virtual Healthcare Conference presentation at 3:00pm ET on Wednesday, April 15, 2026 Webcasts will be available at the
- PREGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsightThe EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations. LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individua
- INSIDERSEC Form 4 filed by Officer Jones Erika4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
- INSIDERSEC Form 4 filed by Officer Hatzis-Schoch Brent4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
- INSIDERSEC Form 4 filed by CHIEF MEDICAL OFFICER Yurasov Sergey4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
- INSIDERSEC Form 4 filed by PRESIDENT & CEO Velleca Mark A.4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
- INSIDERSEC Form 4 filed by CHIEF SCIENTIFIC OFFICER Buck Elizabeth4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
- INSIDERDirector Behbahani Ali was granted 5,208 shares, increasing direct ownership by 6% to 86,649 units (SEC Form 4)4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
- INSIDERDirector Raman Prakash was granted 4,665 shares, increasing direct ownership by 18% to 31,027 units (SEC Form 4)4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)
BDTX FAQ
7 questionsWhat does Black Diamond Therapeutics Inc. do?
Black Diamond Therapeutics, Inc., a biotechnology company, discover and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an irreversible small molecule inhibitor that is designed to block the function of family of oncogenic proteins defined by driver mutations across a range of tumor types, and which affect the epidermal growth factor receptor (EGFR), the tyrosine-protein kinase, or human epidermal growth factor receptor 2. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including allosteric and canonical EGFR...Where does BDTX stock trade?
Black Diamond Therapeutics Inc. (BDTX) is listed on NASDAQ.What sector and industry is BDTX in?
Black Diamond Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Black Diamond Therapeutics Inc. go public?
Black Diamond Therapeutics Inc. (BDTX) completed its IPO in 2020.What are analysts saying about BDTX?
Black Diamond Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Guggenheim: Neutral on 2025-12-03. Recent price targets range from $800.00 to $2000.00.What companies are similar to BDTX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare BDTX side-by-side with any of them on Quantisnow.How can I track BDTX on Quantisnow?
Quantisnow aggregates Black Diamond Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BDTX to receive live email and push alerts on every new disclosure.